Open Access Articles- Top Results for Sirolimus


Systematic (IUPAC) name
Clinical data
Licence data EMA:Link, US FDA:link
  • AU: C
  • US: C (Risk not ruled out)
Pharmacokinetic data
Bioavailability 20%, less after eating food rich in fat
Protein binding 92%
Metabolism Hepatic
Half-life 57–63 hours
Excretion Mostly faecal
53123-88-9 7pxY
PubChem CID 5284616
DrugBank DB00877 7pxY
ChemSpider 10482078 7pxY
UNII W36ZG6FT64 7pxY
KEGG D00753 7pxY
ChEBI CHEBI:9168 7pxN
Chemical data
Formula C51H79NO13
914.172 g/mol
 14pxN (what is this?)  (verify)

Sirolimus (also known as rapamycin) is a chemical that was discovered by Suren Sehgal,[1] as a product of bacteria discovered on Easter Island (the island is also known as Rapa Nui).[2] It was approved by the US Food and Drug Administration in September 1999 and is marketed under the trade name Rapamune by Pfizer (formerly by Wyeth).

Sirolimus was originally developed as an antifungal agent. However, this use was abandoned when it was discovered to have potent immunosuppressive and antiproliferative properties. It has since been shown to prolong the life of mice and might also be useful in the treatment of certain cancers.

Mechanism of action

Unlike the similarly named tacrolimus, sirolimus is not a calcineurin inhibitor, but it has a similar suppressive effect on the immune system. Sirolimus inhibits IL-2 and other cytokines receptor-dependent signal transduction mechanisms, via action on mTOR, and thereby blocks activation of T and B cells. Tacrolimus and cyclosporine inhibit the secretion of IL-2, by inhibiting calcineurin.

The mode of action of sirolimus is to bind the cytosolic protein FK-binding protein 12 (FKBP12) in a manner similar to tacrolimus. Unlike the tacrolimus-FKBP12 complex, which inhibits calcineurin (PP2B), the sirolimus-FKBP12 complex inhibits the mTOR (mechanistic (formerly mammalian) Target Of Rapamycin, rapamycin being another name for sirolimus) pathway by directly binding to mTOR Complex 1 (mTORC1).

mTOR has also been called FRAP (FKBP-rapamycin-associated protein), RAFT (rapamycin and FKBP target), RAPT1, or SEP. The earlier names FRAP and RAFT were coined to reflect the fact that sirolimus must bind FKBP12 first, and only the FKBP12-sirolimus complex can bind mTOR. However, mTOR is now the widely accepted name, since Tor was first discovered via genetic and molecular studies of sirolimus-resistant mutants of Saccharomyces cerevisiae that identified FKBP12, Tor1, and Tor2 as the targets of sirolimus and provided robust support that the FKBP12-sirolimus complex binds to and inhibits Tor1 and Tor2.

Clinical uses

Prevention of transplant rejection

The chief advantage sirolimus has over calcineurin inhibitors is its low toxicity toward kidneys. Transplant patients maintained on calcineurin inhibitors long-term tend to develop impaired kidney function or even chronic renal failure; this can be avoided by using sirolimus instead. It is particularly advantageous in patients with kidney transplants for hemolytic-uremic syndrome, as this disease is likely to recur in the transplanted kidney if a calcineurin-inhibitor is used. However, on October 7, 2008, the FDA approved safety labeling revisions for sirolimus to warn of the risk for decreased renal function associated with its use.

Sirolimus can also be used alone, or in conjunction with calcineurin inhibitors, such as tacrolimus and/or mycophenolate mofetil, to provide steroid-free immunosuppression regimens. Impaired wound healing and thrombocytopenia are a possible side effects of sirolimus; therefore, some transplant centres prefer not to use it immediately after the transplant operation, but instead administer it only after a period of weeks or months. Its optimal role in immunosuppression has not yet been determined, and it remains the subject of a number of ongoing clinical trials.

The absorption of sirolimus into the blood stream from the intestine varies widely between patients, with some patients having up to eight times more exposure than others for the same dose. Drug levels are, therefore, taken to make sure patients get the right dose for their condition. This is determined by taking a blood sample before the next dose, which gives the trough level. However, good correlation is noted between trough concentration levels and drug exposure, known as area under the concentration-time curve, for both sirolimus (SRL) and tacrolimus (TAC) (SRL: r2 = 0.83; TAC: r2 = 0.82), so only one level need be taken to know its pharmacokinetic (PK) profile. PK profiles of SRL and of TAC are unaltered by simultaneous administration. Dose-corrected drug exposure of TAC correlates with SRL (r2 = 0.8), so patients have similar bioavailability of both.[3]

Coronary stent coating

The antiproliferative effect of sirolimus has also been used in conjunction with coronary stents to prevent restenosis in coronary arteries following balloon angioplasty. The sirolimus is formulated in a polymer coating that affords controlled release through the healing period following coronary intervention. Several large clinical studies have demonstrated lower restenosis rates in patients treated with sirolimus-eluting stents when compared to bare-metal stents, resulting in fewer repeat procedures. A sirolimus-eluting coronary stent was marketed by Cordis, a division of Johnson & Johnson, under the tradename Cypher.[4] Such stents, though, may increase the risk of vascular thrombosis.[5]

Adverse effects

Lung toxicity

Lung toxicity is a serious complication associated with sirolimus therapy,[6][7][8][9][10][11][12] especially in the case of lung transplants.[13] The mechanism of the interstitial pneumonitis caused by sirolimus and other macrolide MTOR inhibitors is unclear, and may have nothing to do with the mTOR pathway.[14][15][16] The interstitial pneumonitis is not dose-dependent, but is more common in patients with underlying lung disease.[6][17]

Cancer risk

As with all immunosuppressive medications, in theory, sirolimus may decrease the body's inherent anticancer activity and allow some cancers that would have been naturally destroyed to proliferate. Patients on immunosuppressive medications have a 10- to 100-fold increased risk of cancer compared to the general population.[citation needed] Historically, about 10% of solid organ recipients treated with calcineurin inhibitors develop skin tumours and lymphoma after 70 months. However, data are contradictory regarding calcineurin inhibitors versus sirolimus via UV-induced carcinogenesis-associated processes such as DNA repair, and p53 and MMP expression as a result from different biochemical mechanisms.[18] People who currently have or have already been treated for cancer have a higher rate of tumor progression and recurrence than patients with an intact immune system.[citation needed] These general considerations counsel caution when exploring the potential of sirolimus to combat cancer. However, a plethora of studies indicate, when dosed appropriately, sirolimus can enhance the immune response to tumor targeting[19] or otherwise promote tumor regression in clinical trials.[20] Sirolimus seems to lower the cancer risk in some transplant patients.[21]

Diabetes-like symptoms

Sirolimus inhibits a protein kinase complex known as mTORC1, and this appears to provide most of the beneficial effects of the drug (including life-lengthening in animal studies). Sirolimus also acts on a related complex known as mTORC2. Disruption of mTORC2 produces the diabetes-like symptoms of decreased glucose tolerance and insensitivity to insulin also associated with sirolimus.[22]


The biosynthesis of the rapamycin core is accomplished by a type I polyketide synthase (PKS) in conjunction with a nonribosomal peptide synthetase (NRPS). The domains responsible for the biosynthesis of the linear polyketide of rapamycin are organized into three multienzymes, RapA, RapB, and RapC, which contain a total of 14 modules (figure 1). The three multienzymes are organized such that the first four modules of polyketide chain elongation are in RapA, the following six modules for continued elongation are in RapB, and the final four modules to complete the biosynthesis of the linear polyketide are in RapC.[23] Then, the linear polyketide is modified by the NRPS, RapP, which attaches L-pipecolate to the terminal end of the polyketide, and then cyclizes the molecule, yielding the unbound product, prerapamycin.[24] <div class="thumb tnone" style="margin-left: auto; margin-right:auto; width:99%; max-width:Expression error: Unrecognized punctuation character "[".px;">

Figure 1: Domain organization of PKS of rapamycin and biosynthetic intermediates
Figure 2: Prerapamycin, unbound product of PKS and NRPS
Figure 3: Sequence of "tailoring" steps, which convert unbound prerapamycin into rapamycin

The core macrocycle, prerapamycin (figure 2), is then modified (figure 3) by an additional five enzymes, which lead to the final product, rapamycin. First, the core macrocycle is modified by RapI, SAM-dependent O-methyltransferase (MTase), which O-methylates at C39. Next, a carbonyl is installed at C9 by RapJ, a cytochrome P-450 monooxygenases (P-450). Then, RapM, another MTase, O-methylates at C16. Finally, RapN, another P-450, installs a hydroxyl at C27 immediately followed by O-methylation by Rap Q, a distinct MTase, at C27 to yield rapamycin.[25]

File:Picolinic acid biosynthesis.png
Figure 4: Proposed mechanism of lysine cyclodeaminase conversion of L-lysine to L-pipecolic acid

The biosynthetic genes responsible for rapamycin synthesis have been identified. As expected, three extremely large open reading frames (ORF's) designated as rapA, rapB, and rapC encode for three extremely large and complex multienzymes, RapA, RapB, and RapC, respectively.[23] The gene rapL has been established to code for a NAD+-dependent lysine cycloamidase, which converts L-lysine to L-pipecolic acid (figure 4) for incorporation at the end of the polyketide.[26][27] The gene rapP, which is embedded between the PKS genes and translationally coupled to rapC, encodes for an additional enzyme, an NPRS responsible for incorporating L-pipecolic acid, chain termination and cyclization of prerapamycin. In addition, genes rapI, rapJ, rapM, rapN, rapO, and rapQ have been identified as coding for tailoring enzymes that modify the macrocyclic core to give rapamycin (figure 3). Finally, rapG and rapH have been identified to code for enzymes that have a positive regulatory role in the preparation of rapamycin through the control of rapamycin PKS gene expression.[28] Biosynthesis of this 31-membered macrocycle begins as the loading domain is primed with the starter unit, 4,5-dihydroxocyclohex-1-ene-carboxylic acid, which is derived from the shikimate pathway.[23] Note that the cyclohexane ring of the starting unit is reduced during the transfer to module 1. The starting unit is then modified by a series of Claisen condensations with malonyl or methylmalonyl substrates, which are attached to an acyl carrier protein (ACP) and extend the polyketide by two carbons each. After each successive condensation, the growing polyketide is further modified according to enzymatic domains that are present to reduce and dehydrate it, thereby introducing the diversity of functionalities observed in rapamycin (figure 1). Once the linear polyketide is complete, L-pipecolic acid, which is synthesized by a lysine cycloamidase from an L-lysine, is added to the terminal end of the polyketide by an NRPS. Then, the NSPS cyclizes the polyketide, giving prerapamycin, the first enzyme-free product. The macrocyclic core is then customized by a series of post-PKS enzymes through methylations by MTases and oxidations by P-450s to yield rapamycin.


File:Rapamycin plaque on Easter Island.JPG
A plaque, written in Brazilian Portuguese, commemorating the discovery of sirolimus on Easter Island, near Rano Kau


The antiproliferative effects of sirolimus may have a role in treating cancer. Sirolimus was shown to inhibit the progression of dermal Kaposi's sarcoma in patients with renal transplants. Other mTOR inhibitors, such as temsirolimus (CCI-779) or everolimus (RAD001), are being tested for use in cancers such as glioblastoma multiforme and mantle cell lymphoma. However, these drugs have a higher rate of fatal adverse events in cancer patients than control drugs.[29]

A combination therapy of doxorubicin and sirolimus has been shown to drive AKT-positive lymphomas into remission in mice. Akt signalling promotes cell survival in Akt-positive lymphomas and acts to prevent the cytotoxic effects of chemotherapy drugs, such as doxorubicin or cyclophosphamide. Sirolimus blocks Akt signalling and the cells lose their resistance to the chemotherapy. Bcl-2-positive lymphomas were completely resistant to the therapy; eIF4E-expressing lymphomas are not sensitive to sirolimus.[30][31][32][33]

Tuberous sclerosis complex

Sirolimus also shows promise in treating tuberous sclerosis complex (TSC), a congenital disorder that leaves sufferers prone to benign tumor growth in the brain, heart, kidneys, skin, and other organs. After several studies conclusively linked mTOR inhibitors to remission in TSC tumors, specifically subependymal giant-cell astrocytomas in children and angiomyolipomas in adults, many US doctors began prescribing sirolimus (Wyeth's Rapamune) and everolimus (Novartis's RAD001) to TSC patients off-label. Numerous clinical trials using both rapamycin analogs, involving both children and adults with TSC, are underway in the United States.[34]

Most studies thus far have noted that tumors often regrew when treatment stopped. Theories that claim the drug ameliorates TSC symptoms such as facial angiofibromas, ADHD, and autism are a matter of current research in animal models.

Lifespan extension in mice

Rapamycin was first shown to extend lifespan in eukaryotes in 2006.[35] Powers et al.. showed a dose-responsive effect of rapamycin on lifespan extension in yeast cells. Building on this and other work, in a 2009 study, the lifespans of mice fed rapamycin were increased between 28 and 38% from the beginning of treatment, or 9 to 14% in total increased maximum lifespan. Of particular note, the treatment began in mice aged 20 months, the equivalent of 60 human years. This suggests the possibility of an effective antiaging treatment for humans at an already-advanced age, as opposed to requiring a lifelong regimen beginning in youth.[36] Rapamycin has subsequently been shown to extend mouse lifespan in several separate experiments,[37][38] and is now being tested for this purpose in nonhuman primates (the marmoset monkey),[39] and with an ongoing attempt to organize a study in dogs.[40]

Because rapamycin at high doses can suppress the immune system, people taking rapamycin for transplant or cancer therapy are more susceptible to dangerous infections. Yet paradoxically, rapamycin was shown to enhance the ability of aging mice to mount an immune response to a vaccine against tuberculosis.[41] A similar immunological "rejuvenating" effect was later documented in elderly humans administered a rapamycin analog prior to influenza vaccination),[42] further fueling optimism for the potential of mTOR as a target for anti-aging drugs for humans.

However, is not known whether rapamycin will have similar lifespan-lengthening effects in humans, and study authors caution that the drug should not be used by the general population for this use.[43]

Tuberous sclerosis in mice, with possible relevance to autism

In a study of sirolimus as a treatment for tuberous sclerosis, researchers observed improvements in TSC symptoms which overlap with autism. The researchers discovered that sirolimus regulates one of the same proteins the TSC gene does, but in different parts of the body. They decided to treat mice three to six months old (adulthood in mice lifespans); this increased the TSC mice's intellect to about that of normal mice in as little as three days.[44]

Alzheimer's in mice

Sirolimus reduced brain lesions and prevented the decline of performance in the water maze in mice with a mouse model of Alzheimer's. Because sirolimus is already approved for other indications, it should be easy to start a clinical trial to see whether it works in humans.[45] Recent studies have observed a protective effect against Alzheimer's Disease in preventing cognitive deficits and reducing amyloid-β levels in mouse models. [46]

Muscular dystrophy in mice

Researchers at Washington University School of Medicine in St. Louis observed that nanoparticles coated in sirolimus increases grip strength by 30% and significantly increases cardiac function in mice. The nanoparticle consists of a core of perfluorocarbon and are 200 nm in diameter. The nanoparticle accumulates in areas of inflammation, in this case the muscles where it releases a small dose of sirolimus. This suppresses the immune system and promotes autophagy.[47]

Marijuana-induced amnesia

Andrés Ozaita, of the Universitat Pompeu Fabra in Spain, along with colleagues in France and Germany, focused on THC, the main psychoactive chemical compound in marijuana, which acts on a specific class of receptors known as cannabinoid receptors. These receptors are known to affect the connection strength between neurons.

The scientists found that THC increases the activity of a pathway that promotes protein synthesis in the mouse brain. This transient increase of protein synthesis was mediated specifically by cannabinoid receptors expressed on the brain’s inhibitory neurons, and correlated with long-term memory deficits in mice. The authors also found that inhibition of this signaling pathway by sirolimus prevents THC-induced amnesia in mice.[48]

Systemic lupus erythematosus in mice and humans

Sirolimus improves disease activity and dependence on prednisone in systemic lupus erythematosus (SLE) patients resistant or intolerant to immunosuppressant medications. Sirolimus acts through blocking the activation of its molecular target, the mechanistic target of rapamycin complex 1 (mTORC1). The activation of mTORC1, which is associated with suppression of mTORC2, results in the expansion of proinflammatory CD4-CD8- double-negative (DN) T lymphocytes. These DN T cells produce inflammatory cytokines, interleukin-4 (IL-4) and interleukin-17, and they exhibit predisposition to proinflammatory cell death through necrosis. Increased IL-4 production is responsible for activation of autoantibody-producing B lymphocytes in SLE.[49][50][51][52][53] Sirolimus also blocks disease in lupus-prone mice by reversing the activation of mTORC1.[54] Prospective clinical trial in SLE patients with sirolimus is ongoing.

Other afflictions

Studies in vitro in mice and in humans suggest sirolimus inhibits HIV replication through different mechanisms, including downregulation of the coreceptor CCR5[55] and the induction of autophagy.[56]

In addition, sirolimus is currently being assessed as a therapeutic option for autosomal-dominant polycystic kidney disease (ADPKD). Case reports indicate sirolimus can reduce kidney volume and delay the loss of renal function in patients with ADPKD.[57]

Sirolimus has also been used in preliminary research to combat progeria, a rare disorder that causes individuals to age at an exceedingly rapid pace, leading to death in the early teenage years due to causes such as heart disease or stroke.[58]

Applications in biology research

Rapamycin is used in biology research as an agent for chemically induced dimerization.[59] In this application, rapamycin is added to cells expressing two fusion constructs, one of which contains the rapamycin-binding FRB domain from mTOR and the other of which contains an FKBP domain. Each fusion protein also contains additional domains that are brought into proximity when rapamycin induces binding of FRB and FKBP. In this way, rapamycin can be used to control and study protein localization and interactions.

See also


  1. ^ Vézina C, Kudelski A, Sehgal SN (October 1975). "Rapamycin (AY-22,989), a new antifungal antibiotic". J. Antibiot. 28 (10): 721–6. PMID 1102508. doi:10.7164/antibiotics.28.721. 
  2. ^ Pritchard DI (2005). "Sourcing a chemical succession for cyclosporin from parasites and human pathogens". Drug Discovery Today 10 (10): 688–691. PMID 15896681. doi:10.1016/S1359-6446(05)03395-7. 
  3. ^ McAlister VC, Mahalati K, Peltekian KM, Fraser A, MacDonald AS. (June 2002). "A clinical pharmacokinetic study of tacrolimus and sirolimus combination immunosuppression comparing simultaneous to separated administration.". Ther Drug Monit. 24 (3): 346–50. PMID 12021624. doi:10.1097/00007691-200206000-00004. 
  4. ^ "Cypher Sirolimus-eluting Coronary Stent". Cypher Stent. Retrieved 2008-04-01. 
  5. ^ Shuchman M (2006). "Trading restenosis for thrombosis? New questions about drug-eluting stents". N Engl J Med 355 (19): 1949–52. PMID 17093244. doi:10.1056/NEJMp068234. 
  6. ^ a b Chhajed PN, Dickenmann M, Bubendorf L, Mayr M, Steiger J, Tamm M (2006). "Patterns of pulmonary complications associated with sirolimus". Respiration 73 (3): 367–74. PMID 16127266. doi:10.1159/000087945. 
  7. ^ Morelon E, Stern M, Israël-Biet D et al. (September 2001). "Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients". Transplantation 72 (5): 787–90. PMID 11571438. doi:10.1097/00007890-200109150-00008. 
  8. ^ Filippone EJ, Carson JM, Beckford RA et al. (September 2011). "Sirolimus-induced pneumonitis complicated by pentamidine-induced phospholipidosis in a renal transplant recipient: a case report". Transplant. Proc. 43 (7): 2792–7. PMID 21911165. doi:10.1016/j.transproceed.2011.06.060. 
  9. ^ Pham PT, Pham PC, Danovitch GM et al. (April 2004). "Sirolimus-associated pulmonary toxicity". Transplantation 77 (8): 1215–20. PMID 15114088. doi:10.1097/01.TP.0000118413.92211.B6. 
  10. ^ Mingos MA, Kane GC (December 2005). "Sirolimus-induced interstitial pneumonitis in a renal transplant patient" (PDF). Respir Care 50 (12): 1659–61. PMID 16318648. 
  11. ^ Das BB, Shoemaker L, Subramanian S, Johnsrude C, Recto M, Austin EH (March 2007). "Acute sirolimus pulmonary toxicity in an infant heart transplant recipient: case report and literature review". J. Heart Lung Transplant. 26 (3): 296–8. PMID 17346635. doi:10.1016/j.healun.2006.12.004. 
  12. ^ Delgado JF, Torres J, José Ruiz-Cano M et al. (September 2006). "Sirolimus-associated interstitial pneumonitis in 3 heart transplant recipients". J. Heart Lung Transplant. 25 (9): 1171–4. PMID 16962483. doi:10.1016/j.healun.2006.05.013. 
  13. ^ McWilliams TJ, Levvey BJ, Russell PA, Milne DG, Snell GI (February 2003). "Interstitial pneumonitis associated with sirolimus: a dilemma for lung transplantation". J. Heart Lung Transplant. 22 (2): 210–3. PMID 12581772. doi:10.1016/S1053-2498(02)00564-8. 
  14. ^ Aparicio G, Calvo MB, Medina V et al. (August 2009). "Comprehensive lung injury pathology induced by mTOR inhibitors". Clin Transl Oncol 11 (8): 499–510. PMID 19661024. doi:10.1007/s12094-009-0394-y. 
  15. ^ Paris A, Goupil F, Kernaonet E et al. (January 2012). "[Drug-induced pneumonitis due to sirolimus: an interaction with atorvastatin?]". Rev Mal Respir (in French) 29 (1): 64–9. PMID 22240222. doi:10.1016/j.rmr.2010.03.026. 
  16. ^ Maroto JP, Hudes G, Dutcher JP et al. (May 2011). "Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus". J. Clin. Oncol. 29 (13): 1750–6. PMID 21444868. doi:10.1200/JCO.2010.29.2235. 
  17. ^ Errasti P, Izquierdo D, Martín P et al. (October 2010). "Pneumonitis associated with mammalian target of rapamycin inhibitors in renal transplant recipients: a single-center experience". Transplant. Proc. 42 (8): 3053–4. PMID 20970608. doi:10.1016/j.transproceed.2010.07.066. 
  18. ^ Weischer; Röcken, Martin; Berneburg, Mark et al. (May 2007). "Calcineurin Inhibitors..". Experimental Dermatology 16 (5): 385–393. PMID 17437481. doi:10.1111/j.1600-0625.2007.00555.x. 
  19. ^ Li, Q; Rao, R; Vazzana, J; Goedegebuure, P; Odunsi, K; Gillanders, W; Shrikant, PA (2012). "Regulating mammalian target of rapamycin to tune vaccination-induced CD8(+) T cell responses for tumor immunity". Journal of immunology (Baltimore, Md. : 1950) 188 (7): 3080–7. PMC 3311730. PMID 22379028. doi:10.4049/jimmunol.1103365. 
  20. ^ Easton, JB; Houghton, PJ (2006). "MTOR and cancer therapy". Oncogene 25 (48): 6436–46. PMID 17041628. doi:10.1038/sj.onc.1209886. 
  21. ^ Law BK (October 2005). "Rapamycin: an anti-cancer immunosuppressant?". Crit. Rev. Oncol. Hematol. 56 (1): 47–60. PMID 16039868. doi:10.1016/j.critrevonc.2004.09.009. 
  22. ^ Lamming DW, Ye L, Katajisto P; Ye; Katajisto; Goncalves; Saitoh; Stevens; Davis; Salmon; Richardson; Ahima; Guertin; Sabatini; Baur et al. (March 2012). "Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity". Science 335 (6076): 1638–43. Bibcode:2012Sci...335.1638L. PMC 3324089. PMID 22461615. doi:10.1126/science.1215135. 
  23. ^ a b c Schwecke T, Aparicio JF, Molnár I; Aparicio; Molnar; Konig; Khaw; Haycock; Oliynyk; Caffrey; Cortes; Lester; Bohm; Staunton; Leadlay et al. (August 1995). "The biosynthetic gene cluster for the polyketide immunosuppressant rapamycin". Proc. Natl. Acad. Sci. U.S.A. 92 (17): 7839–43. Bibcode:1995PNAS...92.7839S. PMC 41241. PMID 7644502. doi:10.1073/pnas.92.17.7839. 
  24. ^ Gregory MA, Gaisser S, Lill RE et al. (May 2004). "Isolation and characterization of pre-rapamycin, the first macrocyclic intermediate in the biosynthesis of the immunosuppressant rapamycin by S. hygroscopicus". Angew. Chem. Int. Ed. Engl. 43 (19): 2551–3. PMID 15127450. doi:10.1002/anie.200453764. 
  25. ^ Gregory MA, Hong H, Lill RE et al. (October 2006). "Rapamycin biosynthesis: Elucidation of gene product function". Org. Biomol. Chem. 4 (19): 3565–8. PMID 16990929. doi:10.1039/b608813a. 
  26. ^ Graziani EI (May 2009). "Recent advances in the chemistry, biosynthesis and pharmacology of rapamycin analogs". Nat Prod Rep 26 (5): 602–9. PMID 19387497. doi:10.1039/b804602f. 
  27. ^ Gatto, G. J., Jr.; Boyne, M. T., II; Kelleher,N. L.; Walsh, C. T. (2006). "Biosynthesis of Pipecolic Acid by RapL, a Lysine Cyclodeaminase Encoded in the Rapamycin Gene Cluster". J. Am. Chem. Soc. 128 (11): 3838–47. PMID 16536560. doi:10.1021/ja0587603. 
  28. ^ Aparicio JF, Molnár I, Schwecke T et al. (February 1996). "Organization of the biosynthetic gene cluster for rapamycin in Streptomyces hygroscopicus: analysis of the enzymatic domains in the modular polyketide synthase". Gene 169 (1): 9–16. PMID 8635756. doi:10.1016/0378-1119(95)00800-4. 
  29. ^ Fatal AEs Higher with mTOR Drugs in Cancer. Med Page Today
  30. ^ Sun SY, Rosenberg LM, Wang X et al. (August 2005). "Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition". Cancer Res. 65 (16): 7052–8. PMID 16103051. doi:10.1158/0008-5472.CAN-05-0917. 
  31. ^ Chan S (2004). "Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer". Br J Cancer 91 (8): 1420–4. PMC 2409926. PMID 15365568. doi:10.1038/sj.bjc.6602162. 
  32. ^ Wendel HG, De Stanchina E, Fridman JS; Stanchina; Fridman; Malina; Ray; Kogan; Cordon-Cardo; Pelletier; Lowe et al. (March 2004). "Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy". Nature 428 (6980): 332–7. Bibcode:2004Natur.428..332W. PMID 15029198. doi:10.1038/nature02369. Lay summaryScienceDaily (2004-03-18). 
  33. ^ Novak, Kristine (May 2004). "Therapeutics: Means to an end". Nature Reviews Cancer 4 (5): 332. doi:10.1038/nrc1349. 
  34. ^ Tuberous Sclerosis Alliance (October 2009). "Current Clinical Trials". Retrieved 2009-10-14. 
  35. ^ Powers R.W.; Kaeberlein, M; Caldwell, SD; Kennedy, BK; Fields, S et al. (15 January 2006). "Extension of chronological life span in yeast by decreased TOR pathway signaling". Genes & Development 20 (2): 174–184. PMC 1356109. PMID 16418483. doi:10.1101/gad.1381406. 
  36. ^ Harrison DE, Strong R, Sharp ZD; Strong; Sharp; Nelson; Astle; Flurkey; Nadon; Wilkinson; Frenkel; Carter; Pahor; Javors; Fernandez; Miller et al. (8 July 2009). "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice". Nature 460 (7253): 392–5. Bibcode:2009Natur.460..392H. PMC 2786175. PMID 19587680. doi:10.1038/nature08221. Lay summaryThe Times (2009-07-08). 
  37. ^ Miller RA, Harrison DE, Astle CM, Baur JA, Boyd AR, de Cabo R, Fernandez E, Flurkey K, Javors MA, Nelson JF, Orihuela CJ, Pletcher S, Sharp ZD, Sinclair D, Starnes JW, Wilkinson JE, Nadon NL, Strong R (February 2011). "Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice". J. Gerontol. A Biol. Sci. Med. Sci. 66 (2): 191–201. PMC 3021372. PMID 20974732. doi:10.1093/gerona/glq178. 
  38. ^ Ingram DK, Roth GS (Feb–Mar 2011). "Glycolytic inhibition as a strategy for developing calorie restriction mimetics". Experimental Gerontology 46 (2-3): 148–54. PMID 21167272. doi:10.1016/j.exger.2010.12.001. Retrieved 28 September 2013. 
  39. ^ Tardif, S; Ross, C; Bergman, P; Fernandez, E; Javors, M; Salmon, A; Spross, J; Strong, R; Richardson, A (July 19, 2014 Epub ahead of print]). "Testing Efficacy of Administration of the Antiaging Drug Rapamycin in a Nonhuman Primate, the Common Marmoset". J Gerontol A Biol Sci Med Sci 70: 577–588. PMID 25038772. doi:10.1093/gerona/glu101.  Check date values in: |date= (help)
  40. ^ Check Hayden, Erika (October 30, 2014). "Pet dogs set to test anti-ageing drug". Nature 514 (7524): 546. PMID 25355339. doi:10.1038/514546a. Retrieved 2 April 2015. 
  41. ^ Jagannath, Chinnaswamy; Bakhru, Pearl (2012). "Rapamycin-induced enhancement of vaccine efficacy in mice". Methods Mol Biol. Methods in Molecular Biology 821: 295–303. ISBN 978-1-61779-429-2. PMID 22125073. doi:10.1007/978-1-61779-430-8_18. 
  42. ^ Mannick, JB; Del Giudice, G; Lattanzi, M; Valiante, NM; Paestgaard, J; Huang, B; Lonetto, MA; Maecker, HT; Kovarik, J; Carson, S; Klickstein, LB (December 24, 2014). "mTOR inhibition improves immune function in the elderly". Sci Transl Med 6 (268): 268ra179. doi:10.1126/scitranslmed.3009892. 
  43. ^ Jocelyn Rice (8 July 2009). "First Drug Shown to Extend Life Span in Mammals". Technology Review (Massachusetts Institute of Technology): 1–2. Retrieved 2009-07-09. 
  44. ^ Ehninger D, Han S, Shilyansky C et al. "Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis". Nat. Med. 14 (8): 843–8. PMC 2664098. PMID 18568033. doi:10.1038/nm1788. 
  45. ^ Report
  46. ^ Spilman P, Podlutskaya N, Hart MJ et al. (2010). Ferrari, Pier Francesco, ed. "Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease". PLoS ONE 5 (4): e9979. PMC 2848616. PMID 20376313. doi:10.1371/journal.pone.0009979. 
  47. ^ "Nanoparticles treat muscular dystrophy in mice | Newsroom | Washington University in St. Louis". Retrieved 2014-04-07. 
  48. ^ Cannabinoid modulation of hippocampal long-term memory is mediated by mTOR signaling
  49. ^ Fernandez, D; Bonilla, E; Mirza, N; Niland, B; Perl, A (2006). "Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus". Arthritis & Rheumatism 54 (9): 2983–8. PMC 4034146. PMID 16947529. doi:10.1002/art.22085.  edit
  50. ^ Fernandez, D. R.; Telarico, T; Bonilla, E; Li, Q; Banerjee, S; Middleton, F. A.; Phillips, P. E.; Crow, M. K.; Oess, S; Muller-Esterl, W; Perl, A (2009). "Activation of mammalian target of rapamycin controls the loss of TCRzeta in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation". The Journal of Immunology 182 (4): 2063–73. PMC 2676112. PMID 19201859. doi:10.4049/jimmunol.0803600.  edit
  51. ^ Fernandez, D; Perl, A (2010). "MTOR signaling: A central pathway to pathogenesis in systemic lupus erythematosus?". Discovery medicine 9 (46): 173–8. PMC 3131182. PMID 20350481.  edit
  52. ^ Lai, Z. W.; Borsuk, R; Shadakshari, A; Yu, J; Dawood, M; Garcia, R; Francis, L; Tily, H; Bartos, A; Faraone, S. V.; Phillips, P; Perl, A (2013). "Mechanistic target of rapamycin activation triggers IL-4 production and necrotic death of double-negative T cells in patients with systemic lupus erythematosus". The Journal of Immunology 191 (5): 2236–46. PMC 3777662. PMID 23913957. doi:10.4049/jimmunol.1301005.  edit
  53. ^ Kato, H; Perl, A (2014). "Mechanistic Target of Rapamycin Complex 1 Expands Th17 and IL-4+ CD4-CD8- Double-Negative T Cells and Contracts Regulatory T Cells in Systemic Lupus Erythematosus". The Journal of Immunology 192 (9): 4134–44. PMC 3995867. PMID 24683191. doi:10.4049/jimmunol.1301859.  edit
  54. ^ Caza, T. N.; Fernandez, D. R.; Talaber, G; Oaks, Z; Haas, M; Madaio, M. P.; Lai, Z. W.; Miklossy, G; Singh, R. R.; Chudakov, D. M.; Malorni, W; Middleton, F; Banki, K; Perl, A (2013). "HRES-1/Rab4-mediated depletion of Drp1 impairs mitochondrial homeostasis and represents a target for treatment in SLE". Annals of the Rheumatic Diseases 73: 1888–1897. PMID 23897774. doi:10.1136/annrheumdis-2013-203794.  edit
  55. ^ Donia M, McCubrey JA, Bendtzen K, Nicoletti F (December 2010). "Potential use of rapamycin in HIV infection". Br J Clin Pharmacol 70 (6): 784–93. PMC 3014061. PMID 21175433. doi:10.1111/j.1365-2125.2010.03735.x. 
  56. ^ Campbell GR, Spector SA (March 2011). "Hormonally active vitamin D3 (1{alpha},25-dihydroxycholecalciferol) triggers autophagy in human macrophages that inhibits HIV-1 infection". J Biol Chem 286 (21): 18890–902. PMID 21454634. doi:10.1074/jbc.M110.206110. 
  57. ^ Peces R, Peces C, Pérez-Dueñas V et al. (16 January 2009). "Rapamycin reduces kidney volume and delays the loss of renal function in a patient with autosomal-dominant polycystic kidney disease". NDT Plus (Oxford Journals) 2 (2): 133–5. ISSN 1753-0792. doi:10.1093/ndtplus/sfn210. 
  58. ^ Clue to kids' early aging disease found, July 1, 2011
  59. ^ Rivera, VM; Clackson, T; Natesan, S; Pollock, R; Amara, JF; Keenan, T; Magari, SR; Phillips, T; Courage, NL; Cerasoli F, Jr; Holt, DA; Gilman, M (September 1996). "A humanized system for pharmacologic control of gene expression". Nature Medicine 2 (9): 1028–32. PMID 8782462. doi:10.1038/nm0996-1028. 

External links